VBI Vaccines Inc. operates as a biopharmaceutical company in the United States. It develops eVLP vaccine platform that allows for the design of enveloped (e) virus-like particle vaccines that closely mimic the target virus. The company's lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. It is also developing a thermostable technology platform that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. The company was formerly known as Paulson Capital (Delaware) Corp and changed its name to VBI Vaccines Inc. in July 2014. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.